These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35572599)

  • 1. Editorial: Mucosal Vaccination: Strategies to Induce and Evaluate Mucosal Immunity.
    Kozlowski PA; Mantis NJ; Frey A
    Front Immunol; 2022; 13():905150. PubMed ID: 35572599
    [No Abstract]   [Full Text] [Related]  

  • 2. Mucosal Vaccination With Recombinant
    Wei J; Hegde VL; Yanamandra AV; O'Hara MP; Keegan B; Jones KM; Strych U; Bottazzi ME; Zhan B; Sastry KJ; Hotez PJ
    Front Immunol; 2022; 13():800295. PubMed ID: 35197976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New advances in mucosal vaccination.
    Ranasinghe C
    Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens.
    Gosselin EJ; Bitsaktsis C; Li Y; Iglesias BV
    Arch Immunol Ther Exp (Warsz); 2009; 57(5):311-23. PubMed ID: 19688186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal vaccines: Strategies and challenges.
    Li M; Wang Y; Sun Y; Cui H; Zhu SJ; Qiu HJ
    Immunol Lett; 2020 Jan; 217():116-125. PubMed ID: 31669546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviral vectors for mucosal vaccination against infectious diseases.
    Santosuosso M; McCormick S; Xing Z
    Viral Immunol; 2005; 18(2):283-91. PubMed ID: 16035940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarriers: a versatile approach for mucosal vaccine delivery.
    Mody N; Sharma R; Agrawal U; Vyas SP
    Ther Deliv; 2015 Feb; 6(2):231-45. PubMed ID: 25690089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
    Corthésy B; Bioley G
    Front Immunol; 2018; 9():431. PubMed ID: 29563912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant.
    Shi W; Kou Y; Jiang H; Gao F; Kong W; Su W; Xu F; Jiang C
    Immunol Lett; 2018 Jun; 198():26-32. PubMed ID: 29601940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.
    Rawool DB; Bitsaktsis C; Li Y; Gosselin DR; Lin Y; Kurkure NV; Metzger DW; Gosselin EJ
    J Immunol; 2008 Apr; 180(8):5548-57. PubMed ID: 18390739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Strategies for Mucosal Vaccination.
    Longet S; Lundahl MLE; Lavelle EC
    Bioconjug Chem; 2018 Mar; 29(3):613-623. PubMed ID: 29300463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual mucosa: A new vaccination route for systemic and mucosal immunity.
    Kweon MN
    Cytokine; 2011 Apr; 54(1):1-5. PubMed ID: 21239178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Editorial overview: The march of mucosal vaccines.
    Lavelle EC; Genescà M
    Curr Opin Immunol; 2024 Feb; 86():102408. PubMed ID: 38128438
    [No Abstract]   [Full Text] [Related]  

  • 19. Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination.
    Huang CH; Huang CY; Ho HM; Lee CH; Lai PT; Wu SC; Liu SJ; Huang MH
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of B cells by a dendritic cell-targeted oral vaccine.
    Sahay B; Owen JL; Yang T; Zadeh M; Lightfoot YL; Ge JW; Mohamadzadeh M
    Curr Pharm Biotechnol; 2013; 14(10):867-77. PubMed ID: 24372255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.